MedPath

Analysis of immunological status using CFSE-MLR for de-novo kidney transplant recipients who are treated with Everolimus commencing 3 months after surgery.

Not Applicable
Conditions
After kidney transplantation
Registration Number
JPRN-UMIN000010743
Lead Sponsor
Trasnplantation surgery, Hiroshima University Hospital
Brief Summary

o significant difference was found between reduced Cyclosporine plus Everolimus group and normal dose Cyclosporine group in CFSE-MLR categorization.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

rejection severe proteinuria

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Comparison of CFSE-MLR categorization between reduced Cyclosporine plus Everolimus group and normal dose Cyclosporine group.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath